Spero Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a significant decline in revenue and an increase in net losses compared to the same period in 2025. The company generated no revenue during the three months ended June 30, 2026, a decrease from $14.2 million in the prior year, which included $2.4 million in grant revenue and $11.8 million in collaboration revenue related to its agreement with GlaxoSmithKline (GSK). For the six months ended June 30, 2026, total revenue was $258,000, down from $20.1 million in the same period last year. The net loss for the second quarter was $9.6 million, compared to a loss of $1.7 million in the prior year, while the loss for the first half of 2026 was $16.8 million, slightly higher than the $15.6 million loss reported in 2025.
Operating expenses for Spero Therapeutics decreased to $9.9 million in the second quarter of 2026 from $16.6 million in the same quarter of 2025, primarily due to reduced research and development costs, which fell to $3.4 million from $10.7 million. This reduction was attributed to decreased clinical activities related to the pivotal Phase 3 trial of tebipenem pivoxil, which was stopped early for efficacy and subsequently received FDA approval in June 2026. General and administrative expenses increased slightly to $6.5 million from $5.9 million, reflecting higher professional and consulting fees.
In terms of strategic developments, Spero entered into a significant licensing agreement with Innovent Biologics on July 8, 2026, granting the company exclusive rights to develop and commercialize SP001, a monoclonal antibody targeting CD40L, for various immune-mediated diseases. This agreement includes an upfront payment of $35 million and potential milestone payments totaling approximately $1.05 billion. Additionally, Spero completed a $105 million royalty financing transaction with affiliates of HCRx, which will provide funding based on future GSK proceeds.
As of June 30, 2026, Spero had cash and cash equivalents of $50.8 million, an increase from $40.3 million at the end of 2025. The company anticipates that its current cash position, along with proceeds from the recent financing, will be sufficient to fund operations into the second half of 2029. However, Spero cautioned that it will require additional funding to support ongoing operations and product development beyond this period. The company continues to face risks typical of the biotechnology industry, including the need for successful clinical trials and regulatory approvals to generate revenue from product sales.
About Spero Therapeutics, Inc.
Spero Therapeutics is a biopharmaceutical company focused on developing novel treatments for rare and multi-drug resistant bacterial infections. Its pipeline includes oral and IV antibiotics targeting serious infections like cUTI, HABP/VABP, and NTM pulmonary disease. The company collaborates with partners like GSK and Meiji, leveraging proprietary technology and strategic licensing to address high unmet medical needs in infectious diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov